The evolving role of chemotherapy in androgen-independent (hormone-refractory) prostate cancer (Q36153503)

12 August 2017

1 reference

title

The evolving role of chemotherapy in androgen-independent (hormone-refractory) prostate cancer (English)

1 reference

12 August 2017

1 reference

1 reference

William R Berry

1

1 reference

PubMed ID

15939076

12 August 2017

language of work or name

English

0 references

publication date

1 June 2005

1 reference

12 August 2017

1 reference

12 August 2017

65

1 reference

12 August 2017

6 Suppl

1 reference

12 August 2017

2-7

1 reference

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

12 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.080

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.080

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.080

A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.080

Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: a decade of progress?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.080

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.080

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.080

Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.080

Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.080

A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.080

Weekly administration of docetaxel for symptomatic metastatic hormone‐refractory prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.080

10.1016/J.UROLOGY.2005.03.080

7 January 2021

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

15939076